Ranked #8,085 of 8,699 institutional investors
Stonepine Capital Management, LLC
Bend, OR
$99.5M
US stock portfolio at live prices · today −$1.1M (−1.08%)
Market closed. Prices as of Nov 20, 7:41 AM ET
- Value at quarter end (Q3 2026)
- $120M
- Change from Q2 2026
- −$224.6M (−65.22%)
- Positions
- 63 · 18 new, 17 sold out
- Filed
- Nov 13, 2026
Not counted in the ranking: call options on $39.6M of stock. $2.0M of holdings we could not match to a US listing are included at their reported quarter-end value.
Holdings
Q3 2026 13F, live pricesVSTM 21.0%CAMP 11.2%ADMA 9.39%EOLS 6.84%ELOX 4.09%
| Stock | Shares | Value, live | % of portfolio | vs Q2 2026 |
|---|---|---|---|---|
| VSTM Verastem, Inc. | 3,042,775 | $20.9M | 21.0% | Reduced −9% |
| CAMP Camp4 Therapeutics Corp | 2,786,249 | $11.1M | 11.2% | Added +101% |
| ADMA ADMA Biologics, Inc. | 700,000 | $9.3M | 9.39% | Reduced −5% |
| EOLS Evolus, Inc. | 971,622 | $6.8M | 6.84% | Reduced −39% |
| ELOX Eloxx Pharmaceuticals, Inc. | 381,977 | $4.1M | 4.09% | Reduced −4% |
| RARE Ultragenyx Pharmaceutical Inc. | 210,000 | $3.6M | 3.64% | Added +740% |
| NKTR Nektar Therapeutics | 110,000 | $3.6M | 3.60% | Reduced −9% |
| SUPN Supernus, Inc. | 100,000 | $2.8M | 2.85% | Unchanged |
| MSLE Satellos Bioscience Inc. | 455,058 | $2.6M | 2.65% | Reduced −7% |
| AYTU Aytu BioPharma, Inc. | 964,900 | $2.6M | 2.58% | Added +6% |
| BSX Boston Scientific Corporation | 55,000 | $2.4M | 2.38% | New |
| KZIA Kazia Therapeutics Limited | 377,429 | $2.0M | 2.04% | Added +9% |
| ANTX AN2 Therapeutics, Inc. | 350,877 | $1.8M | 1.84% | Reduced −36% |
| EDSA Edesa Biotech, Inc. | 710,266 | $1.5M | 1.55% | Added +56% |
| XLO Xilio Therapeutics, Inc. | 189,092 | $1.4M | 1.43% | Reduced −16% |
| SRZN Surrozen, Inc. | 44,100 | $1.4M | 1.36% | New |
| KTTA Pasithea Therapeutics Corp. | 2,774,234 | $1.3M | 1.34% | Added +26% |
| PYXS Pyxis Oncology, Inc. | 689,000 | $1.2M | 1.16% | New |
| ZVRA Zevra Therapeutics, Inc. | 100,000 | $907K | 0.91% | Reduced −61% |
| QNRX Quoin Pharmaceuticals, Ltd. | 252,434 | $848K | 0.85% | Added +27% |
| IKT Inhibikase Therapeutics, Inc. | 647,285 | $841K | 0.85% | Added +63% |
| TENX Tenax Therapeutics, Inc. | 588,000 | $817K | 0.82% | Reduced −11% |
| XENE Xenon Pharmaceuticals Inc. | 20,000 | $751K | 0.76% | New |
| CDXS Codexis, Inc. | 676,973 | $711K | 0.71% | Added +517% |
| GOSS Gossamer Bio, Inc. | 63,039 | $708K | 0.71% | New |
| ABEO Abeona Therapeutics Inc. | 282,016 | $691K | 0.69% | Reduced −49% |
| MLTX MoonLake Immunotherapeutics | 60,000 | $662K | 0.67% | Added +20% |
| CLRB Cellectar Biosciences, Inc. | 749,028 | $661K | 0.66% | Added +616% |
| INAB IN8bio, Inc. | 697,852 | $539K | 0.54% | Added +0% |
| CABA Cabaletta Bio, Inc. | 520,000 | $525K | 0.53% | Reduced −43% |
| ACET Adicet Bio, Inc. | 188,201 | $463K | 0.47% | Reduced −23% |
| CTMX CytomX Therapeutics, Inc. | 220,000 | $451K | 0.45% | Added +7% |
| OKUR OnKure Therapeutics, Inc. | 162,818 | $449K | 0.45% | Added +25% |
| XFOR X4 Pharmaceuticals, Inc. | 150,000 | $444K | 0.45% | Reduced −33% |
| ZLAB Zai Lab Limited | 18,998 | $416K | 0.42% | New |
| FEMY Femasys Inc. | 326,770 | $412K | 0.41% | New |
| IRD Opus Genetics, Inc. | 98,147 | $400K | 0.40% | Reduced −3% |
| NGEN NervGen Pharma Corp. | 200,000 | $384K | 0.39% | Reduced −26% |
| ALMS Alumis Inc. | 85,000 | $368K | 0.37% | New |
| ZNTL Zentalis Pharmaceuticals, Inc. | 254,759 | $346K | 0.35% | Added +58% |
| CALC CalciMedica, Inc. | 278,680 | $326K | 0.33% | New |
| LUNG Pulmonx Corporation | 110,479 | $303K | 0.30% | Reduced −86% |
| MXCT MaxCyte, Inc. | 224,881 | $288K | 0.29% | Reduced −70% |
| AEON AEON Biopharma, Inc. | 2,125,748 | $283K | 0.28% | New |
| SINT Sintx Technologies, Inc. | 233,936 | $276K | 0.28% | Added +12% |
| NMRA Neumora Therapeutics, Inc. | 787,269 | $273K | 0.27% | New |
| QTTB Q32 Bio Inc. | 31,200 | $265K | 0.27% | New |
| PLRX Pliant Therapeutics, Inc. | 414,903 | $257K | 0.26% | Added +80% |
| SABS SAB Biotherapeutics, Inc. | 88,108 | $256K | 0.26% | Added +20% |
| EPRX Eupraxia Pharmaceuticals Inc. | 40,000 | $245K | 0.25% | Reduced −8% |
| CRBP Corbus Pharmaceuticals Holdings, Inc. | 95,000 | $231K | 0.23% | Reduced −78% |
| IMA ImageneBio, Inc. | 57,663 | $229K | 0.23% | New |
| QTI QT Imaging Holdings, Inc. | 100,000 | $187K | 0.19% | Unchanged |
| CNSP CNS Pharmaceuticals, Inc. | 39,942 | $156K | 0.16% | Reduced −4% |
| ARDX Ardelyx, Inc. | 51,000 | $156K | 0.16% | New |
| BOLD Boundless Bio, Inc. | 52,547 | $125K | 0.13% | Reduced −66% |
| OCUL Ocular Therapeutix, Inc. | 20,000 | $117K | 0.12% | New |
| CLYM Climb Bio Inc | 10,000 | $93K | <0.1% | New |
| BIOA BioAge Labs, Inc. | 11,948 | $56K | <0.1% | Reduced −40% |
| KLRS Kalaris Therapeutics, Inc. | 33,842 | $46K | <0.1% | Added +12% |
| EVAX Evaxion A/S | 16,566 | $34K | <0.1% | Reduced −6% |
| GERN Geron Corporation | 20,000 | $18K | <0.1% | New |
| EYPT EyePoint, Inc. | 55,000 | $15K | <0.1% | New |
Sold out in Q3 2026
| Stock | Shares held at Q2 2026 | Worth today |
|---|---|---|
| RADX Radiopharm Theranostics Limited | 51,000,000 | $34.3M |
| TELA TELA Bio, Inc. | 2,662,427 | $1.9M |
| SPRB Spruce Biosciences, Inc. | 28,795 | $1.2M |
| NVCT Nuvectis Pharma, Inc. | 40,000 | $794K |
| ORKA Oruka Therapeutics, Inc. | 7,500 | $732K |
| PMVP PMV Pharmaceuticals, Inc. | 536,086 | $702K |
| SENS Senseonics Holdings, Inc. | 48,680 | $433K |
| PHAT Phathom Pharmaceuticals, Inc. | 85,010 | $432K |
| ARVN Arvinas, Inc. | 60,000 | $404K |
| ANL Adlai Nortye Group Ltd. | 24,257 | $220K |
| POCI Precision Optics Corporation, Inc. | 46,390 | $189K |
| HRTX Heron Therapeutics, Inc. | 490,787 | $130K |
| HUMA Humacyte, Inc. | 231,299 | $126K |
| PCSA Processa Pharmaceuticals, Inc. | 55,000 | $93K |
| RNTX Rein Therapeutics Inc. | 218,038 | $80K |
| UPB Upstream Bio, Inc. | 33,432 | $67K |
| OVID Ovid Therapeutics Inc. | 21,300 | $50K |